Skip to main content
    N

    Nuvation Bio Inc (NUVB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NYSE

    $3.86
    -0.13 (-3.26%)

    Market Cap: $1.41B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Nuvation Bio Inc (NUVB) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Nuvation Bio reported EPS of -$0.12, below the -$0.11 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    57%(13/23)
    Avg Surprise
    +6.53%

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus-$0.11
    Range-$0.14 - -$0.03
    15 analysts
    Revenue Consensus
    $45.16M
    Range$32.24M - $79.80M
    15 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus-$0.06
    Range-$0.12 - $0.00
    4 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.03-124.7%
    60d ago-$0.03-87.5%
    30d ago-$0.04-66.7%
    7d ago-$0.03-76.5%
    Current-$0.06
    Revenue Consensus
    $56.73M
    Range$36.60M - $80.00M
    4 analysts

    Next Report

    NUVB's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    NUVB Earnings Call

    The latest NUVB earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 23 quarters below that had an estimate, NUVB beat 13, missed 7 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $44.95M, up 242.6% from $13.12M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.12-$0.11-$0.13 - -$0.09-9.09%MissN/A30 up, 1 downNov 4, 2026$44.95M
    Jun 30, 2026-$0.15-$0.15N/A0.00%In lineN/A10 up, 1 downAug 6, 2026$31.69M
    Mar 31, 2026$0.01-$0.04N/A+123.15%BeatN/A10 up, 0 downMay 4, 2026$83.23M
    Dec 31, 2025-$0.11-$0.09N/A-22.22%MissN/A20 up, 0 downMar 2, 2026$41.87M
    Sep 30, 2025-$0.16-$0.17N/A+5.88%BeatN/A10 up, 0 downNov 3, 2025$13.12M
    Jun 30, 2025-$0.17-$0.17N/A0.00%In lineN/A10 up, 1 downAug 7, 2025$4.83M
    Mar 31, 2025-$0.13-$0.12-$0.13 - -$0.11-8.33%MissN/A2N/AMay 7, 2025$3.08M
    Dec 31, 2024-$0.12-$0.12-$0.14 - -$0.10+2.92%BeatN/A21 up, 0 downMar 6, 2025N/A
    Sep 30, 2024-$0.12-$0.10-$0.18 - -$0.08-20.00%MissN/A51 up, 0 downNov 6, 2024$727000
    Jun 30, 2024-$1.85-$0.05-$0.07 - -$0.05N/AN/AN/A60 up, 0 downAug 5, 2024$1.44M
    Mar 31, 2024-$0.04-$0.05N/A+20.00%BeatN/A50 up, 0 downMay 14, 2024N/A
    Dec 31, 2023-$0.06-$0.10-$0.13 - -$0.09+40.00%BeatN/A60 up, 0 downFeb 29, 2024$264000
    Sep 30, 2023-$0.06-$0.08N/A+25.00%BeatN/A60 up, 0 downNov 2, 2023N/A
    Jun 30, 2023-$0.07-$0.08N/A+12.50%BeatN/A60 up, 0 downAug 3, 2023N/A
    Mar 31, 2023-$0.08-$0.06N/A-33.33%MissN/A60 up, 0 downMay 4, 2023N/A
    Dec 31, 2022-$0.10-$0.11-$0.14 - -$0.08+9.09%BeatN/A60 up, 0 downMar 15, 2023N/A
    Sep 30, 2022-$0.11-$0.15-$0.17 - -$0.11+26.67%BeatN/A70 up, 0 downNov 3, 2022N/A
    Jun 30, 2022-$0.14-$0.11N/A-27.27%MissN/A60 up, 0 downAug 4, 2022N/A
    Mar 31, 2022-$0.08-$0.13N/A+38.46%BeatN/A50 up, 0 downMay 9, 2022N/A
    Dec 31, 2021-$0.12-$0.12-$0.13 - -$0.110.00%In lineN/A60 up, 0 downFeb 28, 2022N/A
    Sep 30, 2021-$0.09-$0.10-$0.12 - -$0.10+10.00%BeatN/A5N/ANov 10, 2021N/A
    Jun 30, 2021-$0.08-$0.10-$0.12 - -$0.08+20.00%BeatN/A5N/AAug 12, 2021N/A
    Mar 31, 2021-$0.11-$0.06-$0.10 - -$0.05-83.33%MissN/A6N/AMay 17, 2021N/A
    Dec 31, 2020-$0.04-$0.05-$0.06 - -$0.04+20.00%BeatN/A3N/AJan 20, 2021N/A
    Sep 30, 2020-$0.04N/AN/AN/AN/AN/AN/AN/ANov 16, 2020N/A
    Jun 30, 2020Not reportedN/AN/AN/ANot reportedN/AN/AN/AAug 14, 2020N/A
    Last 26 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.57, after -$2.13 the year before. It was -$0.08 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.57N/A
    Dec 31, 2024-$2.13N/A
    Dec 31, 2023-$0.27N/A
    Dec 31, 2022-$0.43N/A
    Dec 31, 2021-$0.40N/A
    Dec 31, 2020-$0.08N/A

    Earnings Calls

    The 6 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,000 words across 17 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20269,04017
    2026Q2Jun 30, 20268,77313
    2026Q1Mar 31, 20266,7318
    2025Q4Dec 31, 20259,32812
    2025Q3Sep 30, 20258,24312
    2025Q1Mar 31, 20257,26411

    2026Q3 Earnings Call

    Opening remarks

    Robert DeVita Vice President of Corporate Development and Investor Relations Thank you, and good afternoon, everyone. Earlier today, we issued a press release summarizing our financial results for the quarter ending September 30, 2026, and provided a business update. The press release is available on the Investors section of our website at nuvationbio.com. Today's call includes forward-looking statements, including statements about the therapeutic and commercial potential of IBTROZI and safusidenib, our development plans for taletrectinib, safusidenib, and our drug-drug conjugate platform, along with our plans for future updates from these programs, the components of our anticipated product revenue, our expected milestone payments and spending patterns, and our cash runway and profitability potential. Because such statements deal with future events and are subject to many risks and uncertainties, actual results may differ materially from those in the forward-looking statements. For a full discussion of these risks and uncertainties, please review our quarterly report on Form 10-Q, which we filed with the U.S. Securities and Exchange Commission today. Joining me on today's call are our Founder, President and Chief Executive Officer, Dr. David Hung; our Chief Commercial Officer, Colleen Sjogren; and our Chief Financial Officer, Philippe Sauvage. Now I'll turn the call over to Dr. David Hung. David, please go ahead.

    David Hung Founder, President and Chief Executive Officer Thanks, J.R. Good afternoon, everyone, and thank you all for joining us. Today, I'm pleased to discuss the progress we made across our business in the third quarter. We generated $45 million in overall revenue, driven by another quarter of strong IBTROZI growth. Net U.S. IBTROZI product revenue was $27.5 million, which represented 18% growth from the last quarter. Approximately 160 new patients started treatment with IBTROZI, about 65% of which were in the first-line setting. The commercial signals that matter most to our long-term thesis remain encouraging. Fifteen months into our U.S. launch, we continue to both build a growing base of patients on therapy and strengthen our position in the ROS1 market. IBTROZI has reached an all-time high in its share of active patients receiving a ROS1 TKI and continues to lead in first-line new patient starts with greater than 60% market share as of the end of the quarter. Our revenue growth reflects an expanding active treatment base driven by an increasing proportion of first-line patients that we believe can stay on therapy for years, as seen in our TRUST clinical studies. IQVIA claims data from the third quarter demonstrated a 15% decline in total new patient starts across the ROS1 TKI market. This is further evidenced by a lower volume of ROS1-positive testing alerts from our laboratory data partners.

    Frequently Asked Questions About NUVB

    Did NUVB beat earnings estimates last quarter?

    No. Nuvation Bio reported EPS of -$0.12 for the quarter ended Sep 30, 2026, below the -$0.11 estimate by 9.09%.

    What EPS do analysts expect from NUVB next quarter?

    The consensus EPS estimate for Nuvation Bio for the quarter ending Dec 31, 2026 is -$0.11 from 15 analysts, with estimates from -$0.14 to -$0.03.

    How often does NUVB beat earnings estimates?

    Nuvation Bio beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of +11.54%.